Management

board

Ray Prudo, MD, Executive Chairman
Click to read bio

Ray Prudo, M.D., has been an active investor and developer of healthcare companies for 25 years. Dr. Prudo has been Founder, Chairman, and Chief Executive Officer of Volution and its predecessor company, Varleigh Immuno Pharmaceuticals, since inception in 2008. He is currently a board member of several UK healthcare companies. Dr. Prudo holds an MBBS from the University of London, and an FRCP(C) from the Royal College of Physicians and Surgeons of Canada.

Gur Roshwalb, MD, MBA, Chief Executive Officer
Click to read bio

Joined Akari as CEO in March, 2013. From April 2008 to February 2013, Dr. Roshwalb was a Vice President at Venrock, where he was an investment professional on the healthcare team investing in both private and public companies. From May 2004 to March 2008, he was a vice president and equity analyst at Piper Jaffray, publishing research on specialty pharmaceutical companies. Prior to Piper, Dr. Roshwalb was in private practice in New York and Board Certified in Internal Medicine. He received his MD from Albert Einstein College of Medicine and his MBA from the NYU Stern School of Business. Dr. Roshwalb trained in internal medicine at the Mount Sinai medical center, where he also served as Chief Resident in 1997-1998.

Mr. Dov Elefant, Chief Financial Officer
Click to read bio

Joined Akari as the Chief Financial Officer since January 11, 2012. From March 2011 until January 2012, he was Chief Financial Officer of Althera Medical Ltd. and from March 2009 to February 2011 he performed consulting services to a number of companies. He was also the Corporate Controller, from March 2007 to February 2009 for Lev Pharmaceuticals (OTCBB:LEVP), which was acquired by ViroPharma in 2008,Controller and Vice President of Finance and Administration at EpiCept Corporation (NASDAQ:EPCT.PK) from December 1999 to March 2007,Assistant Controller at Tetragenex Pharmaceuticals from November 1998 to October 1999 and held other accounting and finance roles from March 1991 to October 1998. Mr. Elefant holds a B.S. in accounting from Yeshiva University.

Mr. Clive Richardson, Chief Operations Officer
Click to read bio

Clive Richardson was Head of Operations for Volution. Prior Volution, Mr. Richardson served as consultant to Varleigh Immuno Pharmaceuticals since inception in 2008. Prior to working for Volution and Varleigh, Mr. Richardson served as a member of the board of directors for a range of international healthcare companies, including CIS Healthcare Ltd. and Clinisys Ltd. Mr. Richardson was formerly Head of Equities Research for Investec Bank, and worked as a strategy consultant for L.E.K. Consulting. Mr Richardson holds an M.A. in Zoology from Trinity College, Oxford University.

Dr. Wynne Weston-Davies, Medical Director
Click to read bio

Wynne Weston-Davies, MRCS, LRCP, MB BS, FRCS, ECFMG, has 30 years of biopharmaceutical drug development experience, and was Medical Director of Volution since 2014. From 2009 to 2014, he served as the medical director at Varleigh. Prior to 2009, Dr. Weston-Davies was Medical Director for Evolutec Group Plc, a publicly-listed UK biotechnology company focused on the discovery and development of drugs from immuno-modulatory molecules found in the saliva of blood-feeding parasites. He has worked for a number of global pharmaceutical companies, including Bristol Myers Squibb from 1979-1992, where he headed up departments responsible for Phase I through Phase IV clinical trials. Dr. Weston-Davies has been a director of multiple health care companies, and initially worked as a general and colorectal surgeon at several UK teaching hospitals. Dr. Weston-Davies gained his initial medical qualifications at London University before becoming a Fellow of the Royal College of Surgeons.

Dr. Miles Nunn, Chief Scientific Officer
Click to read bio

Miles Nunn was Chief Scientific Officer for Volution since April 2014. Prior to Volution, he worked at the Natural Environment Research Council (NERC) for 16 years. He discovered Volution’s lead drug Coversin, and is an inventor on several other patents. Dr. Nunn was formerly the Scientific Research Manager for Evolutec Group Plc, Director of Amplion Ltd., and a Principal Investigator for the Natural Environment Research Council. His scientific interests center on the structural and functional interactions between parasite-derived molecules and host defense responses, in particular complement, and on exploitation of the associated information and parasite molecules for drug development. Dr. Nunn holds a D.Phil. from Oxford University, and M.Sc. from University College London.

Robert M. Shaw, General Counsel & Secretary
Click to read bio

Joined Akari in February 2016. From 2010 to 2016 he was General Counsel at Kenyon & Kenyon LLP. From 2008 to 2010 he was Vice President, Acting General Counsel, and Secretary at KV Pharmaceutical Company. From 2004 to 2008, he was Senior Vice President, General Counsel & Secretary at Pliva, Inc. From 1998 to 2004, he was Executive Vice President, Chief Administrative Officer, General Counsel & Secretary at Savient Pharmaceuticals, Inc. From 1979 to 1998, he held various positions at BASF Corporation, Hoechst Celanese Corporation, Fish & Neave, and Synnestvedt & Lechner. Mr. Shaw holds a B.A. in Chemistry from Amherst College and a J.D. from the School of Law at Washington University in St. Louis.